Investment group SV Life Sciences said today it is rebranding to SV Health Investors.
The Boston-based company said the new moniker will “better reflect the firm’s longstanding strategy and multi-sector focus.”
The investment group said it targets early-stage opportunities in biotechnology, early-stage and revenue stage medical device opportunities and growth equity investments in later-stage businesses in healthcare and digital health fields, according to a press release.
In January, SV joined a ‘significant round of growth capital’ for medtech developer Bardy Diagnostics and its Carnation cardiac monitor and arrhythmia detection device.